{"title":"在病毒抑制的HIV-1患者中使用darunavir、cobicistat、emcitrabine和替诺福韦alafenamide的单片方案是控制HIV的适当治疗选择","authors":"Priya Kathuria","doi":"10.22237/crp/1625097720","DOIUrl":null,"url":null,"abstract":"A clinical decision report using:\n Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34. https://doi.org/10.1016/S2352-3018(17)30179-0\n for a patient with viriologically suppressed HIV-1.","PeriodicalId":10422,"journal":{"name":"Clinical Research In Practice: The Journal of Team Hippocrates","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV\",\"authors\":\"Priya Kathuria\",\"doi\":\"10.22237/crp/1625097720\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A clinical decision report using:\\n Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34. https://doi.org/10.1016/S2352-3018(17)30179-0\\n for a patient with viriologically suppressed HIV-1.\",\"PeriodicalId\":10422,\"journal\":{\"name\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22237/crp/1625097720\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research In Practice: The Journal of Team Hippocrates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22237/crp/1625097720","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV
A clinical decision report using:
Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34. https://doi.org/10.1016/S2352-3018(17)30179-0
for a patient with viriologically suppressed HIV-1.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
